Iksel

Roman name

Ixel

Pharmacokinetics

Well absorbed from the digestive tract. Bioavailability is about 85%. C_max is approximately 2 hours Linking blood plasma is about 13%. Metabolised mainly by conjugation with glukuronova acid. T_1/2-8 pm Write mainly kidneys (about 90%).

Indications

Depressive disorders of varying degrees of severity.

Pregnancy and lactation

Contraindicated. At the time of treatment should stop breastfeeding.

Contraindications

Hypersensitivity, giperplazia prostate cancer, simultaneous inhibition of MAO A and B, selective inhibitors of reverse takeover serotonin, adrenaline, norarenalina, clonidine, digoxin, moklobemida, toloxton; Pregnancy, breast-feeding, age and 15 years of age.

Side-Effects

Dizziness, a sense of anxiety, increased sweating, tides, rapid heartbeat, tremor, difficulty urinating, dry mouth, nausea, vomiting, constipation.

Patient interaction

Incompatible with MAO inhibitors and serotoninergicakimi control (type triptofana or fenfluramina). Changes level of lithium in blood.

Overdosing

Unlikely. Specific antidotes not. Treatment of symptomatic.

Precautions

With the utmost care appoint patients with adenoma prostate, and seizures in pripadkah disease, hypertension, cardiomyopathy. Between receiving MAO inhibitors and Iksela a two-week interval. Patients with kidney failure to reduce doses depending on Cl creatinine. There shall be no use of alcohol. It should not be used in conjunction with the drivers of vehicles and people skills relate to the high concentration of attention.

Storage conditions

In a dry, cool place where the temperature is above 30 ° C

Shelf life

3 years

The registration

011787/01-2000

Directory → Neurotropic funds → 24.2.1 → Iksel